FIGURE 5.

(A) Combining pyrosequencing (PSQ) and immunohistochemistry (IHC) to determine MGMT status in glioblastoma. The refined methylated group included patients from hypermethylated and gray zone groups with low IHC scores, whereas the refined unmethylated group was comprised of patients from unmethylated and gray zone groups with high IHC scores. (B) Compared with PSQ alone (threshold: 12%, blue line) and IHC alone (threshold: 30%, orange line), the combined strategy (red line) significantly improved survival prediction efficiency. (C, D) Prognosis difference for refined methylated and unmethylated patients was more prominent (C, PFS; D, OS). AUC, area under the receiver operating characteristic curve